Cardio Diagnostics Holdings, Inc. (CDIO) Stock Analysis & Investment Frameworks
Cardio Diagnostics Holdings, Inc. (CDIO) stock analysis on Invetso. Review Cardio Diagnostics Holdings, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Cardio Diagnostics Holdings, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Cardio Diagnostics Holdings, Inc. Key Financial Metrics
- Market Cap: $4.96M
- Revenue: $14825.00
- ROE: -82.27%
- ROIC: -82.84%
- Dividend Yield: N/A
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Cardio Diagnostics Holdings, Inc. Investment Frameworks
Invetso analyzes Cardio Diagnostics Holdings, Inc. (CDIO) across the following frameworks:
- Cardio Diagnostics Holdings, Inc. 10Y Growth Potential
- Cardio Diagnostics Holdings, Inc. Scenario Analysis
- Cardio Diagnostics Holdings, Inc. Risks & Opportunities
- Cardio Diagnostics Holdings, Inc. Economic Moat
- Cardio Diagnostics Holdings, Inc. Business Model
- Cardio Diagnostics Holdings, Inc. Management
- Cardio Diagnostics Holdings, Inc. SWOT Analysis
- Cardio Diagnostics Holdings, Inc. Porter's 5 Forces
- Cardio Diagnostics Holdings, Inc. PESTLE Analysis
- Cardio Diagnostics Holdings, Inc. ESG Analysis